Skip to main content
. Author manuscript; available in PMC: 2010 Apr 12.
Published in final edited form as: Future Med Chem. 2009 Apr;1(1):95–118. doi: 10.4155/fmc.09.6

Table 5.

Pentasaccharides.

graphic file with name nihms-133110-f0007.jpg

Study Compound Assays* Activity Lit. no.‡ Ref.
Martin-Lomas
(2000)		 IG-41 Lipogenesis
PDH phosphatase
cAMP-dependent protein kinase		 Inactive 1a [36]
Misek (1992) IG-42 Lipolysis 70% inhibition at 132 μM,
IC50= 60 μM		 VSG-IPG [4]
Glucose-6-phosphatase activity 90% inhibitionat 160 μM,
IC50 = 109 μM
Fructose-1,6-bisphosphatase activity 100% inhibition at 226 μM,
IC50= 136 μM.
Gluconeogenesis 67% inhibitionat 102 μM,
IC50= 84 μM
Misek (1992) Protein phosphorylation/
dephosphorylation		 Blocked IPT-dependent
phosphorylation at 200 μM
~ 90% dephosphorylation at
150 μM, IC50 = 75 μM		 VSG-IPG [4]
Frick (1998) IG-43 Lipogenesis Activity‘A’§ 20 [45]
Frick (1998) IG-44 Lipogenesis Activity‘C’§ 29 [45]
Frick (1998) IG-45 Lipogenesis Activity‘B’§ 23 [45]
Frick (1998) IG-46 Lipogenesis Activity‘C’§ 13 [45]
Frick (1999) 44% MIR, EC50 = 40 μM Q [101]
Glucose transport 18% MIR, EC50 = 30 μM
*

Details of assays (in alphabetical order) are given in the text.

‡

The number assigned to this compound in the cited publication.

§

Note: for Muller’s SAR study [45] aggregate activities were reported as follows: “A”, MIR < 20%; “B”, MIR 20–49%, EC20 25–200 μM; “C”, MIR 50–80%, EC50 10–100 μM; “D”, MIR > 80%, EC50 3–30 μM.

IPG: Inositol phosphate-glycan; Lit. no.: Literacy number; MIR: Maximal insulin response.